Finch Therapeutics’ Investigational Drug CP101 Granted Breakthrough Therapy Designation from FDA for Recurrent C. Difficile Infection

February 8, 2019

TPTF invest in Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, in Series B-1 funding. Currently, Finch is actively enrolling patients with recurrent Clostridium difficile (C. difficile) infection Phase II clinical study to assess the safety and efficacy of an investigational drug CP101. The study drug is an oral capsule that is administered in a single dose.